Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04404283
Recruitment Status : Recruiting
First Posted : May 27, 2020
Last Update Posted : February 2, 2021
Sponsor:
Information provided by (Responsible Party):
Seagen Inc.

Tracking Information
First Submitted Date  ICMJE May 21, 2020
First Posted Date  ICMJE May 27, 2020
Last Update Posted Date February 2, 2021
Actual Study Start Date  ICMJE August 20, 2020
Estimated Primary Completion Date November 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 13, 2020)
  • PFS per blinded independent central review (BICR) in the ITT population [ Time Frame: Up to 1 year ]
    Time from the date of randomization to the date of first documentation of PD per BICR or to death due to any cause, whichever occurs first.
  • PFS per BICR in the CD30-positive population [ Time Frame: Up to 1 year ]
    Time from the date of randomization to the date of first documentation of PD per BICR or to death due to any cause, whichever occurs first.
Original Primary Outcome Measures  ICMJE
 (submitted: May 21, 2020)
  • PFSa per blinded independent central review (BICR) in the ITT population [ Time Frame: Up to 1 year ]
    Time from the date of randomization to the date of first documentation of PD per BICR or to death due to any cause, whichever occurs first.
  • PFS per BICR in the CD30-positive population [ Time Frame: Up to 1 year ]
    Time from the date of randomization to the date of first documentation of PD per BICR or to death due to any cause, whichever occurs first.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 21, 2020)
  • Objective response rate (ORR) per BICR [ Time Frame: Up to 1 year ]
    Proportion of subjects with complete response (CR) or partial response (PR) according to the Lugano Criteria for Response Assessment (Cheson 2014).
  • Overall survival (OS) in the ITT population [ Time Frame: Up to 18 months ]
    me from the date of randomization to date of death due to any cause.
  • OS in the CD30+ population [ Time Frame: Up to 18 months ]
    Time from the date of randomization to date of death due to any cause.
  • Complete response (CR) rate [ Time Frame: Up to 1 year ]
    Time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (Cheson 2014) or death due to any cause, whichever comes first.
  • Duration of objective response [ Time Frame: Up to 1 year ]
    Time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression (Cheson 2014) or death due to any cause, whichever comes first.
  • Incidence of adverse events [ Time Frame: Up to 1 year ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Official Title  ICMJE A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Brief Summary

This study is being done to see if adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma (DLBCL). Participants in this study will have DLBCL that has come back or not gotten better with treatment.

Patients will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," patients and their doctors will not know whether a patient gets brentuximab vedotin or placebo. All patients in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Diffuse Large B-cell Lymphoma
Intervention  ICMJE
  • Drug: Brentuximab vedotin
    1.2 mg/kg administered via intravenous infusion every 3 weeks
  • Drug: Rituximab
    375 mg/m^2 administered via intravenous infusion on Cycle 1 Day 1. 1400 mg via subcutaneous injection permitted every 3 weeks from Cycle 2 Day 1 through end of treatment.
  • Drug: Lenalidomide
    20 mg orally daily
  • Other: Placebo
    Administered via intravenous infusion every 3 weeks
Study Arms  ICMJE
  • Experimental: Experimental Arm
    Brentuximab vedotin + lenalidomide + rituximab
    Interventions:
    • Drug: Brentuximab vedotin
    • Drug: Rituximab
    • Drug: Lenalidomide
  • Active Comparator: Control Arm
    Placebo + lenalidomide + rituximab
    Interventions:
    • Drug: Rituximab
    • Drug: Lenalidomide
    • Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 21, 2020)
400
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2025
Estimated Primary Completion Date November 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Participants with relapsed or refractory diffuse and transformed large B-cell lymphoma (R/R DLBCL). DLBCL and cell of origin (GCB versus non-GCB) will be histologically determined by local pathology assessment for the purposes of study eligibility and stratification.
  • Participants must have R/R disease following 2 or more lines of prior systemic therapy.
  • Participants must be HSCT or CAR-T ineligible according to the investigator and must meet at least one of the following criteria:

    1. One or more co-morbidities, including cardiac, pulmonary, renal or hepatic dysfunction that in the opinion of the Investigator make the subject medically unfit to received HSCT or CAR-T therapy
    2. Active disease following induction and salvage chemotherapy
    3. Inadequate stem cell mobilization (for HSCT)
    4. Relapse following prior HSCT or CAR-T
    5. Unable to receive CAR-T therapy due to financial, geographic, or insurance issues
  • Participants will need to have a formalin-fixed paraffin-embedded tumor tissue (obtained ≤4 weeks before Day 1) submitted to the central pathology lab.
  • An Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
  • Participants must have fluorodeoxyglucose (FDG)-avid disease by positron emission tomography (PET) and bidimensional measurable disease of at least 1.5 cm by computed tomography (CT), as assessed by the site radiologist within 28 days of Day 1.
  • Participants must be registered into the mandatory lenalidomide REMS® program and be willing to comply with its requirements. Per standard lenalidomide REMS® program requirements, all physicians who prescribe lenalidomide for research subjects enrolled into this trial, must be registered in, and must comply with, all requirements of the lenalidomide REMS® program.

Exclusion Criteria:

  • History of another malignancy within 2 years before the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy
  • History of progressive multifocal leukoencephalopathy (PML)
  • Active cerebral/meningeal disease related to the underlying malignancy. Subjects with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior CNS disease has been effectively treated and without progression for at least 3 months.
  • Any uncontrolled Grade 3 or higher (per NCI CTCAE version 5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study drug. Routine antimicrobial prophylaxis is permitted
  • Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with immunotherapy that is not completed 3 weeks prior to first dose of study drug, unless underlying disease has progressed on treatment
  • Participants who are breastfeeding
  • Known hypersensitivity to any study drug or excipient contained in the drug formulation of the study drugs
  • Known to be positive for hepatitis B by surface antigen expression. Known to be positive for hepatitis C infection (positive by polymerase chain reaction [PCR] or on antiviral therapy for hepatitis C within the last 6 months). Participants who have been treated for hepatitis C infection are permitted if they have documented sustained virologic response of 12 weeks.
  • Participants with previous allogeneic HSCT if they meet either of the following criteria:

    1. <100 days from HSCT
    2. Active acute or chronic graft-versus-host disease (GVHD) or receiving immunosuppressive therapy as treatment for or prophylaxis against GVHD
  • Previous treatment with brentuximab vedotin or lenalidomide
  • Current therapy with immunosuppressive medications (including steroids), other systemic anti-neoplastic, or investigational agents

    a) Prednisone (or equivalent) ≤10 mg/day may be used for non-lymphomatous purposes

  • Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class III-IV within 6 months prior to the first dose of study drugs
  • Congestive heart failure, Class III or IV, by the NYHA criteria
  • Grade 2 or higher peripheral sensory or motor neuropathy at baseline
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Seagen Trial Information Support 866-333-7436 clinicaltrials@seagen.com
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04404283
Other Study ID Numbers  ICMJE SGN35-031
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Seagen Inc.
Study Sponsor  ICMJE Seagen Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Robert Sims, MD Seagen Inc.
PRS Account Seagen Inc.
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP